American Medical Innovation and Investment Act of 2024
The source supplies the latest action, but no lifecycle stage.
Latest action (27 Dec 2024): Reported (Amended) by the Committee on Ways and Means. H. Rept. 118-958, Part I.
What this bill does
This bill, the American Medical Innovation and Investment Act of 2024, aims to expand Medicare coverage and streamline certain processes. It would require Medicare to cover the detection of cognitive impairment during annual wellness visits and initial preventive physical exams, using tools identified by the National Institute on Aging. The bill also seeks to improve the process for Medicare coverage decisions, including setting time limits for certain determinations and requiring explanations for rejected requests. Additionally, it addresses Medicare coverage for external infusion pumps and home-administered drugs, as well as guidance on payment for remote monitoring devices and prescription digital therapeutics.
The bill would directly affect Medicare beneficiaries by potentially increasing access to cognitive impairment screenings and other services. It would also impact healthcare providers and suppliers who furnish these services. The bill is currently in Congress, having been introduced and then "ordered to be reported in the nature of a substitute (amended)" by a vote of 40-0. This means the bill has passed through a committee and is one step closer to potentially being considered by the full House of Representatives for a vote.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Timeline
27 Dec 2024
Reported (Amended) by the Committee on Ways and Means. H. Rept. 118-958, Part I.
Common questions
- What does H.R. 8816 do?
- This bill, the American Medical Innovation and Investment Act of 2024, aims to expand Medicare coverage and streamline certain processes. It would require Medicare to cover the detection of cognitive impairment during annual wellness visits and initial preventive physical exams, using tools identified by the National Institute on Aging. The bill also seeks to improve the process for Medicare coverage decisions, including setting time limits for certain determinations and requiring explanations for rejected requests. Additionally, it addresses Medicare coverage for external infusion pumps and home-administered drugs, as well as guidance on payment for remote monitoring devices and prescription digital therapeutics. The bill would directly affect Medicare beneficiaries by potentially increasing access to cognitive impairment screenings and other services. It would also impact healthcare providers and suppliers who furnish these services. The bill is currently in Congress, having been introduced and then "ordered to be reported in the nature of a substitute (amended)" by a vote of 40-0. This means the bill has passed through a committee and is one step closer to potentially being considered by the full House of Representatives for a vote.
- Has H.R. 8816 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 8816. Check the latest action and official source below.
- Who sponsored H.R. 8816?
- H.R. 8816 was sponsored by Rep. Buchanan, Vern [R-FL-16] (R-FL), with 0 cosponsors.
- What's the latest action on H.R. 8816?
- Reported (Amended) by the Committee on Ways and Means. H. Rept. 118-958, Part I. (27 Dec 2024).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Access to Medical Supplies Act
Lower Premiums, Faster Payments Act
More bills from Rep. Buchanan, Vern [R-FL-16]
AI Tax Integrity Act of 2026
AI Fraud Accountability Act
ASAP Act
DETECT Act of 2025
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.